

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;
AND
(2) CHANGES IN COMPOSITIONS OF THE REMUNERATION
COMMITTEE AND THE NOMINATION COMMITTEE**

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board announces that, with effect from July 26, 2024, Mr. Liu has tendered his resignation as an independent non-executive Director in order to focus on his other business engagements, and Mr. Zheng has been appointed as an independent non-executive Director.

**CHANGES IN COMPOSITIONS OF THE REMUNERATION COMMITTEE AND THE
NOMINATION COMMITTEE**

The Board further announces that, following Mr. Liu's resignation as a Director, he has also ceased to be the member of each of the Remuneration Committee and the Nomination Committee, and Mr. Zheng has been appointed as the member of each of the Remuneration Committee and the Nomination Committee, all with effect from July 26, 2024.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the "**Company**") announces that Mr. Liu Daozhi ("**Mr. Liu**") has tendered his resignation as an independent non-executive Director with effect from July 26, 2024 in order to focus on his other business engagements.

Mr. Liu has confirmed that he has no disagreement with the Board and that he is not aware of any other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its sincere gratitude to Mr. Liu for his contribution to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Zheng Junwei (“**Mr. Zheng**”) has been appointed as an independent non-executive Director with effect from July 26, 2024. The biographical details of Mr. Zheng are set out as follows:

Mr. Zheng, aged 45, is the independent non-executive Director since July 26, 2024. Before joining our Company, Mr. Zheng has been committed to promoting the investment in China and international cooperation by enterprises of China Association of Enterprises with Foreign Investment (中國外商投資企業協會) (“**CAEFI**”) members since he became the vice president of CAEFI since 2017. Since September 2018, Mr. Zheng initiated and organized 12 enterprises of CAEFI members engaging in biotechnology innovation to establish the CAEFI Biotechnology Innovation Working Committee Innovation Committee (生物科技創新工作委員會) (“**BIC**”) and has been serving as its chairman since then. In addition, Mr. Zheng served in the Special Commissioner’s Office of the Ministry of Commerce in Fuzhou (商務部駐福州特派員辦事處) as office manager from 2004 to 2017. Mr. Zheng graduated from the School of International Relations, National University of Defense Technology, PLA (中國人民解放軍國防科技大學國際關係學院) (formerly known as Nanjing Institute of International Relations (南京國際關係學院)) in July 2003 with a bachelor’s degree in international economics.

Pursuant to the letter of appointment entered into between the Company and Mr. Zheng, he shall serve until the next annual general meeting of the Company, at which time Mr. Zheng is eligible for re-election pursuant to the articles of association of the Company. According to the terms of the letter of appointment, Mr. Zheng is entitled to an annual salary of RMB200,000, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Save as disclosed above, as at the date of this announcement, Mr. Zheng has confirmed each of the matters as follows: (i) that he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) that he does not currently hold any other position with the Company or any of its subsidiaries; (iii) that he does not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) that he has confirmed his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”); (v) that he did not and does not have any past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as such term is defined in the Listing Rules) of the Company; (vi) that there are no other factors that may affect his independence at the time of his appointment; and (vii) does not have any interest in the shares or underlying shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no information in relation to the appointment of Mr. Zheng as a Director that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

CHANGES IN COMPOSITIONS OF THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE

Following Mr. Liu's resignation as a Director, he has also ceased to be the member of each of the remuneration committee of the Board (the "**Remuneration Committee**") and the nomination committee of the Board (the "**Nomination Committee**") and Mr. Zheng has been appointed as the member of each of the Remuneration Committee and the Nomination Committee, all with effect from July 26, 2024.

The Board would like to take this opportunity to express its warmest welcome to Mr. Zheng for joining the Board.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
July 26, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as an executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*